THE ROLE OF EPSTEIN-BARR VIRUS IN HAEMATOLOGICAL MALIGNANCIES
DOI:
https://doi.org/10.31435/ijitss.4(52).2026.6800Keywords:
EBV, Lymphoma, Burkitt lymphoma, Hodgkin lymphoma, Vaccine, CarcinogenesisAbstract
The majority of adults worldwide are infected with the Epstein-Barr virus (EBV). It was the first human virus to be linked to cancers and is now considered a causative factor in the development of a broad group of B-cell, T-cell and NK-cell neoplasms. This narrative review summarises the role of EBV in haematological malignancies. A structured search of PubMed/MEDLINE, Scopus, and Web of Science was conducted for English-language publications available up to October 2026, supplemented by current guidance from international health authorities. It covers pathogenesis, the clinical features and prognostic meaning of EBV in eight entities, diagnosis and prevention. EBV acts through latent proteins such as LMP1, LMP2A and EBNA2, through viral microRNAs, and through changes in host signalling, antigen presentation, immune checkpoints and the tumour microenvironment. Deletions and variants of the viral genome add a further layer. EBV is found in nearly all endemic Burkitt lymphoma, extranodal NK/T cell lymphoma, in a minority of sporadic Burkitt lymphoma and diffuse large B-cell lymphoma. Prognostic meaning differs between entities. The presence of an EBV infection was associated with a poorer prognosis in diffuse large B-cell lymphoma, NK/T cell lymphoma and, in a meta-analysis, Hodgkin lymphoma. In plasmablastic lymphoma the largest cohort found lower survival rate in EBV-negative disease. Epstein-Barr virus-encoded RNA (EBER) in situ hybridisation remains the diagnostic standard. Plasma EBV DNA adds prognostic and monitoring value, but assays and cut-offs are not standardised. Rituximab prophylaxis and DNA surveillance lower the risk of post-transplant lymphoproliferative disorder in selected groups. Due to the high complexity of the EBV virus, no vaccine has yet been developed against it.
References
Xiao, Q., Liu, Y., Li, T., Wang, C., He, S., Zhai, L., Yang, Z., Zhang, X., Wu, Y., & Liu, Y. (2025). Viral oncogenesis in cancer: from mechanisms to therapeutics. Signal Transduction and Targeted Therapy, 10(1), 151. https://doi.org/10.1038/s41392-025- 02197-9
Wong, Y., Meehan, M. T., Burrows, S. R., Doolan, D. L., & Miles, J. J. (2021). Estimating the global burden of Epstein–Barr virus-related cancers. Journal of Cancer Research and Clinical Oncology, 148(1), 31–46. https://doi.org/10.1007/s00432-021-03824-
Cohen, J. I., Mocarski, E. S., Raab-Traub, N., Corey, L., & Nabel, G. J. (2013). The need and challenges for development of an Epstein-Barr virus vaccine. Vaccine, 31, B194–B196. https://doi.org/10.1016/j.vaccine.2012.09.041
Donzel, M., Bonjour, M., Combes, J., Broussais, F., Sesques, P., Traverse-Glehen, A., & De Martel, C. (2022). Lymphomas associated with Epstein-Barr virus infection in 2020: Results from a large, unselected case series in France. EClinicalMedicine, 54, 101674. https://doi.org/10.1016/j.eclinm.2022.101674
Amarillo, M. E., Lindl, K., Lombardi, M. G., Preciado, M. V., De Matteo, E., & Chabay, P. (2025). Pandemic-Driven Shifts in Epstein-Barr Virus (EBV) Epidemiology: Single Center study. Viruses, 17(3), 375. https://doi.org/10.3390/v17030375
Quintanilla-Martinez, L., Swerdlow, S. H., Tousseyn, T., Barrionuevo, C., Nakamura, S., & Jaffe, E. S. (2022). New concepts in EBV-associated B, T, and NK cell lymphoproliferative disorders. Archiv Für Pathologische Anatomie Und Physiologie Und Für Klinische Medicin, 482(1), 227–244. https://doi.org/10.1007/s00428-022-03414-4
Malpica, L., Marques‐Piubelli, M. L., Beltran, B. E., Chavez, J. C., Miranda, R. N., & Castillo, J. J. (2024). EBV ‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk‐stratification, and management. American Journal of Hematology, 99(10), 2002–2015. https://doi.org/10.1002/ajh.27430
Frontzek, F., Staiger, A. M., Wullenkord, R., Grau, M., Zapukhlyak, M., Kurz, K. S., Horn, H., Erdmann, T., Fend, F., Richter, J., Klapper, W., Lenz, P., Hailfinger, S., Tasidou, A., Trautmann, M., Hartmann, W., Rosenwald, A., Quintanilla-Martinez, L., Ott, G., & ... Lenz, G. (2023). Molecular profiling of EBV associated diffuse large B-cell lymphoma. Leukemia, 37(3), 670–679. https://doi.org/10.1038/s41375-022-01804-w
Hu, J., Zhang, X., Tao, H., & Jia, Y. (2022). The prognostic value of Epstein−Barr virus infection in Hodgkin lymphoma: A systematic review and meta-analysis. Frontiers in Oncology, 12, 1034398. https://doi.org/10.3389/fonc.2022.1034398
Bailly, J., Jenkins, N., Chetty, D., Mohamed, Z., Verburgh, E. R., & Opie, J. J. (2022). Plasmablastic lymphoma: An update. International Journal of Laboratory Hematology, 44(S1), 54–63. https://doi.org/10.1111/ijlh.13863
Alabiad, M. A., Said, W. M. M., Saad, R. H. F., Balata, R., Mahmoud, A. A., Metwally, E. A., Shalaby, A. M., Samy, W., Yehia, A. M., Yahia, A. I. O., Alorini, M., & Abdelrahman, D. I. (2024). Epstein-Barr virus promotes tumorigenicity and worsens hodgkin lymphoma prognosis by activating JAK/STAT and NF-ΚB signaling pathways. PubMed, 49(2), 88– 100. https://doi.org/10.30476/ijms.2023.97287.2896
Richter, J., John, K., Staiger, A. M., Rosenwald, A., Kurz, K., Michgehl, U., Ott, G., Franzenburg, S., Kohler, C., Finger, J., Oschlies, I., Paul, U., Siebert, R., Spang, R., Burkhardt, B., & Klapper, W. (2021). Epstein–Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features. British Journal of Haematology, 196(3), 681–689. https://doi.org/10.1111/bjh.17874
Lim, J. Q., Huang, D., Chan, J. Y., Laurensia, Y., Wong, E. K. Y., Cheah, D. M. Z., Chia, B. K. H., Chuang, W., Kuo, M., Su, Y., Cai, Q., Feng, Y., Rao, H., Feng, L., Wei, P., Chen, J., Han, B., Lin, G., Cai, J., & ... Ong, C. K. (2022). A genomic‐augmented multivariate prognostic model for the survival of natural‐killer/T‐cell lymphoma patients from an international cohort. American Journal of Hematology, 97(9), 1159–1169. https://doi.org/10.1002/ajh.26636
Kato, S., Hamada, M., Okamoto, A., Yamashita, D., Miyoshi, H., Arai, H., Satou, A., Gion, Y., Sato, Y., Tsuyuki, Y., Miyata-Takata, T., Takata, K., Asano, N., Takahashi, E., Ohshima, K., Tomita, A., Hosoda, W., Nakamura, S., & Okuno, Y. (2024). EBV+ nodal T/NK-cell lymphoma associated with clonal hematopoiesis and structural variations of the viral genome. Blood Advances, 8(9), 2138–2147. https://doi.org/10.1182/bloodadvances.2023012019
Xie, Y., Wang, T., & Wang, L. (2020). Hydroa vacciniforme-like lymphoproliferative disorder: A study of clinicopathology and whole-exome sequencing in Chinese patients. Journal of Dermatological Science, 99(2), 128–134. https://doi.org/10.1016/j.jdermsci.2020.06.013
Hirai, Y., Yamamoto, T., Kimura, H., Ito, Y., Tsuji, K., Miyake, T., Morizane, S., Suzuki, D., Fujii, K., & Iwatsuki, K. (2012). Hydroa Vacciniforme Is Associated with Increased Numbers of Epstein–Barr Virus–Infected γδT Cells. Journal of Investigative Dermatology, 132(5), 1401–1408. https://doi.org/10.1038/jid.2011.461
Khine, H. T., Sato, Y., Hamada, M., Umeda, M., Iizuka, A., Son, S., Arai, H., Kojima, Y., Watanabe, T., Naruse, A., Goto, K., Ohshima, K., Akutsu, Y., Nakaguro, M., Satou, A., Kataoka, H., Ito, Y., Sawada, A., Kato, S., & ... Kimura, H. (2025). Association of Epstein-Barr virus genomic alterations with human pathologies. Blood, 146(13), 1533– 1545. https://doi.org/10.1182/blood.2024028055
Kaymaz, Y., Oduor, C. I., Aydemir, O., Luftig, M. A., Otieno, J. A., Ong’echa, J. M., Bailey, J. A., & Moormann, A. M. (2020). Epstein-Barr Virus Genomes Reveal Population Structure and Type 1 Association with Endemic Burkitt Lymphoma. Journal of Virology, 94(17). https://doi.org/10.1128/jvi.02007-19
Kim, I. E., Oduor, C., Stamp, J., Luftig, M. A., Moormann, A. M., Crawford, L., & Bailey, J. A. (2025). Incorporation of Epstein–Barr viral variation implicates significance of Latent Membrane Protein 1 in survival prediction and prognostic subgrouping in Burkitt lymphoma. International Journal of Cancer, 156(11), 2188–2199. https://doi.org/10.1002/ijc.35384
Begic V, Korac P, Gasparov S, Rozman M, Simicic P, Zidovec-Lepej S. Molecular characterisation of Epstein-Barr virus in classical Hodgkin lymphoma. Int J Mol Sci. 2022, 23, 15635. DOI 10.3390/ijms232415635
Keane, C., Tobin, J., Gunawardana, J., Francis, S., Gifford, G., Gabrielli, S., Gill, A., Stevenson, W., Talaulikar, D., Gould, C., Jain, S., Birch, S., Hertzberg, M., & Gandhi, M. K. (2019). The tumour microenvironment is immuno‐tolerogenic and a principal determinant of patient outcome in EBV‐positive diffuse large B‐cell lymphoma. European Journal of Haematology, 103(3), 200–207. https://doi.org/10.1111/ejh.13274
Toh, J., Reitsma, A. J., Tajima, T., Younes, S. F., Ezeiruaku, C., Jenkins, K. C., Peña, J. K., Zhao, S., Wang, X., Lee, E. Y., Glass, M. C., Kalesinskas, L., Ganesan, A., Liang, I., Pai, J. A., Harden, J. T., Vallania, F., Vizcarra, E. A., Bhagat, G., & ... Martinez, O. M. (2024). Multi-modal analysis reveals tumor and immune features distinguishing EBV-positive and EBV-negative post-transplant lymphoproliferative disorders. Cell Reports Medicine, 5(12), 101851. https://doi.org/10.1016/j.xcrm.2024.101851
Bednarska, K., Chowdhury, R., Tobin, J. W. D., Swain, F., Keane, C., Boyle, S., Khanna, R., & Gandhi, M. K. (2023). Epstein–Barr virus‐associated lymphomas decoded. British Journal of Haematology, 204(2), 415–433. https://doi.org/10.1111/bjh.19255
Loghavi, S., Alayed, K., Aladily, T. N., Zuo, Z., Ng, S., Tang, G., Hu, S., Yin, C. C., Miranda, R. N., Medeiros, L. J., & Khoury, J. D. (2015). Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients. Journal of Hematology & Oncology, 8(1), 65. https://doi.org/10.1186/s13045-015-0163-z
Di Ciaccio, P. R., Polizzotto, M. N., Cwynarski, K., Gerrie, A. S., Burton, C., Bower, M., Kuruvilla, J., Montoto, S., McKay, P., Fox, C. P., Milliken, S., Jiamsakul, A., Osborne, W., Collins, G. P., Manos, K., Linton, K. M., Iyengar, S., Kassam, S., Limei, M. P., & ... Hamad, N. (2023). The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma. Blood, 143(2), 152–165. https://doi.org/10.1182/blood.2023021348
Sausen, D. G., Poirier, M. C., Spiers, L. M., & Smith, E. N. (2023). Mechanisms of T cell evasion by Epstein-Barr virus and implications for tumor survival. Frontiers in Immunology, 14, 1289313. https://doi.org/10.3389/fimmu.2023.1289313
Huang, Y., Rao, H., Yan, S., Wang, F., Wu, Q., Feng, Y., & Zhang, Y. (2017). Serum EBV EA- IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution. Annals of Hematology, 96(8), 1331–1342. https://doi.org/10.1007/s00277-017-3013-y
Cohen, J. I. (2015). Epstein–barr virus vaccines. Clinical & Translational Immunology, 4(1), e32. https://doi.org/10.1038/cti.2014.27
Kong, I. Y., & Giulino-Roth, L. (2024). Targeting latent viral infection in EBV-associated lymphomas. Frontiers in Immunology, 15, 1342455. https://doi.org/10.3389/fimmu.2024.1342455
Tajima, T., Martinez, O. M., Bernstein, D., Boyd, S. D., Gratzinger, D., Lum, G., Sasaki, K., Tan, B., Twist, C. J., Weinberg, K., Armstrong, B., Desai, D. M., Mazariegos, G. V., Chin, C., Fishbein, T. M., Tekin, A., Venick, R. S., Krams, S. M., & Esquivel, C. O. (2024). Epstein–Barr virus‐associated post‐transplant lymphoproliferative disorders in pediatric transplantation: A prospective multicenter study in the United States. Pediatric Transplantation, 28(4), e14763. https://doi.org/10.1111/petr.14763
Ludvigsen, L. U. P., Thomsen, M. K., Kro, G. B., Pedersen, R. M., Gramkow, A., Åsberg, A., Bjerre, A. K., Thiesson, H. C., Midtvedt, K., Ivarsen, P., Jensen-Fangel, S., Bibby, B. M., Hamilton-Dutoit, S., D’Amore, F., Reisæter, A. V., & Jespersen, B. (2026). Epstein-Barr virus infection monitoring in kidney transplant recipients (EVITA study)—investigating the clinical significance of EBV-DNAemia and the risk of early-onset PTLD. American Journal of Transplantation. https://doi.org/10.1016/j.ajt.2026.07.012
Mah, J. K., Tam, P. C., Chang, Y., Saullo, J. H., Baker, A. W., Maziarz, E. K., Messina, J. A., Sim, B., Abusalem, L., Hanna, S., Pipeling, M. R., Snyder, L. D., Reynolds, J. M., Wolfe, C. R., Lee, M. J., Alexander, B. D., & Heldman, M. R. (2024). Limited utility of Epstein– Barr virus (EBV) surveillance for predicting post-transplant lymphoproliferative disorders in adult EBV seropositive lung transplant recipients. Journal of Clinical Virology, 176, 105758. https://doi.org/10.1016/j.jcv.2024.105758
Marjańska, A., Pogorzała, M., Dziedzic, M., Czyżewski, K., Richert-Przygońska, M., Dębski, R., Bogiel, T., & Styczyński, J. (2024). Impact of prophylaxis with rituximab on EBV- related complications after allogeneic hematopoietic cell transplantation in children. Frontiers in Immunology, 15, 1427637. https://doi.org/10.3389/fimmu.2024.1427637
Fujiwara-Kuroda, A., Iwashiro, N., & Kimura, N. (2020). A case of resected pulmonary lymphomatoid granulomatosis. Respiratory Medicine Case Reports, 32, 101327. https://doi.org/10.1016/j.rmcr.2020.101327
Derbyshire, J., Fornelli, R., & Mascia, B. (2021). EBV positive lymphomatoid granulomatosis following dental extractions. Ear Nose & Throat Journal, 102(4), NP154–NP156. https://doi.org/10.1177/0145561321997536
Ha, J. Y., Cho, H., Sung, H., Jung, A. R., Lee, Y. S., Lee, S., Ryu, J., Chae, E. J., Kim, K. W., Huh, J., Park, C., Kim, D., Kim, S., & Yoon, D. H. (2020). Superiority of Epstein-Barr virus DNA in the plasma over whole blood for prognostication of extranodal NK/T cell lymphoma. Frontiers in Oncology, 10, 594692. https://doi.org/10.3389/fonc.2020.594692
Chen, J., Zhou, J., Cheng, F., Chen, D., Guan, F., Zhang, E., He, J., Cai, Z., & Zhao, Y. (2024). Role of plasma EBV-DNA load and EBER status on newly diagnosed peripheral T-cell lymphoma. Journal of Cancer Research and Clinical Oncology, 150(4), 181. https://doi.org/10.1007/s00432-024-05702-9
Han, B., Hur, K., Ohn, J., Kim, T. M., Jeon, Y. K., Kim, Y. C., & Mun, J. (2020b). Hydroa vacciniforme-like lymphoproliferative disorder in Korea. Scientific Reports, 10(1), 19294. https://doi.org/10.1038/s41598-020-76345-2
Oh, S. J., Lee, J., Park, J., Lee, J. H., Cho, J., Ko, Y., & Lee, D. (2021). Hydroa Vacciniforme- Like lymphoproliferative Disorder in Korea: Prognostic implication of clinical signs and whole blood Epstein-Barr virus DNA. Annals of Dermatology, 33(3), 222. https://doi.org/10.5021/ad.2021.33.3.222
Wang, X., Liang, Y., Yang, Y., Li, W., Wang, G., Wang, S., Li, Y., & Zhang, M. (2021). Hydroa vacciniforme‐like lymphoproliferative disorder: A clinicopathological, immunohistochemical, and prognostic study of 24 cases in China. The Journal of Dermatology, 48(9), 1315–1326. https://doi.org/10.1111/1346-8138.15944
Volaric, A. K., & Fedoriw, Y. (2024). Epstein-Barr virus-associated B-cell lymphoproliferative disorders and lymphomas: Diagnostic overlaps and defining features. Human Pathology, 156, 105697. https://doi.org/10.1016/j.humpath.2024.105697
Zhang, X., Zhao, B., Ding, M., Song, S., Kang, Y., Yu, Y., Xu, M., Xiang, T., Gao, L., Feng, Q., Zhao, Q., Zeng, M., Krummenacher, C., & Zeng, Y. (2020). A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection. Theranostics, 10(13), 5704–5718. https://doi.org/10.7150/thno.42494
Escalante, G. M., Foley, J., Mutsvunguma, L. Z., Rodriguez, E., Mulama, D. H., Muniraju, M., Ye, P., Barasa, A. K., & Ogembo, J. G. (2020). A Pentavalent Epstein-Barr Virus-Like Particle Vaccine Elicits High Titers of Neutralizing Antibodies against Epstein-Barr Virus Infection in Immunized Rabbits. Vaccines, 8(2), 169. https://doi.org/10.3390/vaccines8020169
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Kamil Rutkowski, Karina Udrycka, Kacper Wrzosek, Aleksandra Zmieniecka, Martyna Waszczyk, Agata Zielińska, Magdalena Ślifierska, Paulina Kwiecień

This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.

